Plasma Cell Disorder Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting plasma cell disorder clinical trials across 5 countries. Studies span Phase 1, Phase 2. Top locations include Charlotte, North Carolina, United States, Little Rock, Arkansas, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Plasma Cell Disorder Trials at a Glance

8 actively recruiting trials for plasma cell disorder are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Charlotte, Little Rock, and Atlanta. Lead sponsors running plasma cell disorder studies include Wake Forest University Health Sciences, Institute of Hematology & Blood Diseases Hospital, China, and Heidelberg Pharma AG.

Browse plasma cell disorder trials by phase

Treatments under study

About Plasma Cell Disorder Clinical Trials

Looking for clinical trials for Plasma Cell Disorder? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Plasma Cell Disorder trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Plasma Cell Disorder clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 1

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

Plasma Cell Disorder
University of Arkansas18 enrolled1 locationNCT06313502
Recruiting

Pre-malignant States to Hematologic Malignancies in Firefighters

Non-Hodgkin LymphomaMultiple MyelomaLeukemia+3 more
Wake Forest University Health Sciences300 enrolled1 locationNCT06870760
Recruiting

Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders

Plasma Cell Disorders
Mayo Clinic240 enrolled1 locationNCT06252948
Recruiting

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

Multiple MyelomaSmoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)+2 more
Wake Forest University Health Sciences1,665 enrolled1 locationNCT06644625
Recruiting
Phase 1Phase 2

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

Plasma Cell Disorder
University of Maryland, Baltimore30 enrolled1 locationNCT07075510
Recruiting
Phase 2

Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

Plasma Cell DisordersSolitary Bone PlasmacytomaPlasmacytoma of Bone
Institute of Hematology & Blood Diseases Hospital, China21 enrolled1 locationNCT07115667
Recruiting
Phase 1Phase 2

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Multiple MyelomaPlasma Cell Disorder
Heidelberg Pharma AG78 enrolled16 locationsNCT04879043